assignment
Recruiting

Evaluation of Nabpaclitaxel-PIPAC Combined with Systemic Nabpaclitaxel-Gemcitabine in Pancreatic Cancer with Peritoneal Metastases: A Phase II Study

Trial ID
2024-518938-81-00
Protocol
Nab-PIPAC

Register record, history and transparency: CTIS.eu

Trial statistics

science
3
test molecules
location_city
1
research site
public
1
country
medical_information
1
disease
person_search
1
investigator

Diseases & Conditions

Pancreatic carcinoma

Objectives

The primary objective of this study is to evaluate the **antitumoral activity** of combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and systemic Nabpaclitaxel-Gemcitabine chemotherapy in patients with pancreatic cancer with peritoneal metastases. This is assessed in terms of Disease Control Rate (DCR), which includes patients experiencing Complete Response, Partial Response, or Stable Disease for a duration of 16 weeks or more, according to RECIST criteria version 1.1. The clinical relevance of this objective lies in its potential to improve treatment outcomes for patients with this aggressive form of cancer, offering insights into the efficacy of this combined therapeutic approach.

Secondary objectives include: - Evaluating the feasibility and safety of the treatment regimen, further assessing its antitumoral activity, and evaluating overall and progression-free survival, as well as quality of life (QoL). - Exploratory objectives involve evaluating the pharmacokinetics of Nabpaclitaxel-PIPAC, assessing the nutritional status of patients during the study period, and conducting translational analysis to identify and validate biomarkers responsible for response or resistance to Nabpaclitaxel-Gemcitabine and PIPAC treatments.

Participants

The clinical trial focuses on evaluating the antitumoral activity of combined Nabpaclitaxel-PIPAC and systemic Nabpaclitaxel-Gemcitabine chemotherapy for **pancreatic cancer** with peritoneal metastases. The study population includes both male and female participants aged 18 years and older. Participants are required to have adequate bone marrow and renal function, as well as a life expectancy of at least three months. The trial does not include a vulnerable population. Participants must have histological or cytological proof of pancreatic cancer with evidence of peritoneal carcinomatosis. The trial population was selected based on specific inclusion criteria, such as an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and no contraindications for laparoscopy or the drugs used in the study. The sponsor has not provided information regarding the total number of participants. Lifestyle considerations such as diet and physical activity are not specified in the available data.

Plans and Procedures

The clinical trial is designed to evaluate the **antitumoral activity** of a combined treatment regimen involving Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and systemic Nabpaclitaxel-Gemcitabine chemotherapy for patients with pancreatic cancer with peritoneal metastases. This is a single-arm, open-label, phase II trial. The primary objective is to assess the Disease Control Rate (DCR) according to RECIST criteria v. 1.1, which includes patients experiencing complete response, partial response, or stable disease for at least 16 weeks. The trial is expected to run from November 8, 2021, to February 28, 2025.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to confirm eligibility based on criteria such as age, bone marrow function, renal function, and absence of contraindications for the study drugs. Following the screening, participants will receive treatment over a maximum period of 12 months, involving six cycles of systemic chemotherapy combined with three PIPAC cycles. Follow-up visits will be scheduled to monitor treatment compliance, safety, and toxicity, as well as to assess the antitumoral activity through peritoneal biopsies and quality of life scores. The end-of-study visit will evaluate the primary and secondary endpoints, including progression-free survival and overall survival.

The expected length of participant involvement is approximately 12 months, with conditions for early termination including significant adverse events, disease progression, or withdrawal of consent. Participants must adhere to the study protocol, including the use of effective contraception for male subjects, to remain in the trial. The trial will also explore translational research endpoints, such as genomic and transcriptomic profiles from biopsies, to further understand the treatment's impact on tumor biology.

Treatment

The clinical trial involves the administration of **GEMCITABINE**, an antineoplastic agent classified as a pyrimidine analog. The pharmaceutical form of GEMCITABINE is a solution for infusion, and it is administered intravenously. The dosage is set at a maximum of 1000 mg/m² per day, with a total maximum dose of 1000 mg/m². The treatment period is limited to a maximum of 12 weeks. GEMCITABINE is a chemically derived active substance, and its administration is monitored to ensure compliance with the dosing schedule.

**PACLITAXEL** is also utilized in this trial, presented as a concentrate for solution for injection. It is administered via two routes: intravenously and intraperitoneally. When administered intravenously, the maximum daily dose is 125 mg/m², with a total maximum dose of 125 mg/m². For intraperitoneal administration, the maximum daily dose is 112.5 mg/m², with a total maximum dose of 112.5 mg/m². The treatment duration for PACLITAXEL is also capped at 12 weeks. PACLITAXEL is categorized under antineoplastics, specifically taxanes, which are derived from alkaloids from plants and other natural products. Compliance with the dosing regimen is closely monitored throughout the trial.

Efficacy

The efficacy of the treatment in this clinical trial will be assessed primarily through the **Disease Control Rate (DCR)**, which is defined as the combined incidence of complete response, partial response, and stable disease for a duration of at least 16 weeks. This will be measured during the study treatments and at the end of the treatment visit, following the RECIST criteria version 1.1. Secondary endpoints include the assessment of compliance to treatment, safety and toxicity, antitumoral activity, quality of life, progression-free survival, and overall survival. Compliance will be evaluated by tracking the number of patients unable to complete the prescribed cycles of chemotherapy and the reasons for any discontinuation or postponement. Safety and toxicity will be assessed by recording the number of patients experiencing major and minor toxicities, as defined by CTCAE version 5.0, and postoperative complications according to the Clavien-Dindo classification.

The antitumoral activity will also be evaluated through pathological tumor response using the Peritoneal Regression Grading Score (PRGS) from peritoneal biopsies collected during each PIPAC procedure. A reduction in PRGS during subsequent biopsies will indicate a response. Additionally, modifications in the Peritoneal Cancer Index (PCI) will be recorded by the surgeon. Quality of life will be assessed using changes in scores from the QLQ-C30 questionnaire at various time points. Progression-free survival is defined as the time from treatment start to radiologic progression, clinical progression, or death, whichever occurs first. Overall survival is defined as the time from study treatment start to death. Exploratory endpoints include the intravenous area under the curve (AUC) of paclitaxel, its concentration in peritoneal samples, and nutritional parameters collected through various methods. Translational research endpoints will explore the germline mutational profile, genomic and transcriptomic profiles of peritoneal metastases biopsies, tumor cells and tissue microenvironments, and circulating cytokines and immune cell profiles.

Inclusion and Exclusion Criteria

check_circle

Inclusion Criteria

  • Age ≥ 18 years
  • Willing and able to provide written and informed consent
  • Histological or cytological proof of pancreatic cancer
  • Metastatic pancreatic carcinoma with evidence of peritoneal carcinomatosis determined by the treating physician, based on abdominal CT-scan or MR and/or diagnostic laparotomy or laparoscopy
  • Evaluable disease defined by RECIST 1.1 criteria
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Life expectancy of at least 3 months
  • No contraindication for laparoscopy
  • No contraindication for drugs used in the study
  • Adequate bone marrow function: Absolute neutrophil count ≥ 1500 cell./mm3; Platelets ≥ 100000 cell./mm3
  • Hemoglobin ≥ 9 g/dl
  • Adequate renal function (serum creatinine up to 1.5 times the maximal limit of the local laboratory) or else based upon clinical evaluation
  • Resolution of all toxic effects of prior therapies or surgical procedures to Grade ≤ 1 (except alopecia and peripheral neuropathy)
  • In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) should be below 2.5 x the upper limit of normal (ULN). If the patient has liver metastases, ALT and AST should be < 5 x ULN
  • Total bilirubin ≤ ULN, or total bilirubin 1.5 x ULN with direct bilirubin ≤ ULN of the laboratory in subjects with documented Gilbert's Syndrome
  • If screening assessments are abnormal, chemistry assessments may be repeated up to two times; subjects may receive appropriate supplementation prior to re-assessment
  • Confirmed negative serum pregnancy test (beta-hCG) within 72 hours before starting study treatment for patients with pre- or peri-menopausal status
  • Male subject must, even if surgically sterilized (ie, status post-vasectomy): Agree to practice highly effective barrier contraception (use condoms) during the entire study treatment period and through 120 days after the last dose of study drugs. For subjects (who have not undergone vasectomy) with female partners of childbearing potential, the subject and his partner must in addition to condoms, use highly effective contraceptive measures when engaging in sexual intercourse throughout the study, and for at least 120 days after the last dose of study drugs (ie oral contraceptive and condoms, intrauterine device).
cancel

Exclusion Criteria

  • Advanced metastatic systemic disease with clinical deterioration
  • Patients with extrabdominal tumor spread
  • Patients with a germline or somatic pathogenic variant involving an (Homologous Recombination Repair) HRR-related gene
  • Symptoms of gastrointestinal occlusion and total parenteral nutritional support
  • Patients defined as “refractory” to previous systemic treatment with Nabpaclitaxel and Gemcitabine administered for locally advanced pancreatic cancer (patients treated with Nabpaclitaxel-Gemcitabine for a locally advanced disease may be included if PM developed after at least 6 months from the end of previous chemotherapy)
  • History of severe and unexpected reactions to Nabpaclitaxel or Gemcitabine
  • Severe cardiac disease (recent myocardial ischemia, severe arrhythmias, severe cardiac failure)
  • Known hypersensitivity reaction to drugs chemically related to Nabpaclitaxel, Gemcitabine and their excipients
  • Clinical disease progression after first 2 months of systemic Nabpaclitaxel Gemcitabine chemotherapy
  • Any concurrent severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk of associated with study participation or investigational product administration or may interfere with compliance with study procedures or the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into the study;
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive beta-HCG laboratory test
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing of study treatment and through 120 days after the last dose of study drug. Highly effective contraception methods include: Total abstinence (when this is in line with the preferred and usual lifestyle of the Subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Tubal ligation at least six weeks before taking study treatment. Male sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject. Combination of the following: Placement of an intrauterine device (IUD) or intrauterine system (IUS); Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository

Trial Status by Country

Country Status Start of Recruitment Planned Patients
Italy ItalyRecruiting08 Nov 202138

Sites & Investigators

Investigational Products

Details about the medicinal products being studied in this clinical trial.

Product Name Role in Trial Formulation Administration Max Daily Dose Treatment Duration EU MP Number
GEMCITABINE
Test—INTRAVENOUS100012SUB07892MIG
PACLITAXEL
Test—INTRAVENOUS12512SUB09583MIG
PACLITAXEL
Test—INTRAPERITONEAL USE112.512SUB09583MIG

Conditions Studied in This Trial

Interventions Studied in This Trial

vaccines
Gemcitabine
127 trials

Also investigated for

Non-small cell lung cancer 11Pancreatic carcinoma 11Cholangiocarcinoma 10Pancreatic carcinoma metastatic 10
vaccines
Paclitaxel
271 trials

Also investigated for

Non-small cell lung cancer 49Ovarian cancer 20Breast cancer 19Triple negative breast cancer 18